|
Sign In to gain access to subscriptions and/or personal tools.
|
Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis
M. Petri
Division of Molecular and Clinical Rheumatology, Johns Hopkins University School of Medicine, Suite 7500, 1830 E. Monument Street, Baltimore, MD 21205, USA
Hydroxychloroquine is used by 35% of SLE patients enrolled in the Baltimore Lupus Cohort. Eighty per cent of patients who took hydroxychloroquine at cohort entry remain on it six years later. In addition to its role for disease manifestations of lupus, hydroxy chloroquine may be indicated for the prevention of disease or treatment-induced com plications, including hyperlipidemia, diabetes mellitus, liver function test elevation and thrombosis.
Key Words: hydroxychloroquine • thrombosis • hyperlipidemia • diabetes mellitus • liver func tion tests
Lupus, Vol. 5, No. 1 suppl,
S16-S22 (1996)
DOI: 10.1177/096120339600500105
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
U. Bergstrom, L. T. H. Jacobsson, and C. Turesson
Cardiovascular morbidity and mortality remain similar in two cohorts of patients with long-standing rheumatoid arthritis seen in 1978 and 1995 in Malmo, Sweden
Rheumatology,
December 1, 2009;
48(12):
1600 - 1605.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V Bellomio, A Spindler, E Lucero, A Berman, R Sueldo, H Berman, M Santana, M. Molina, V Gongora, G Cassano, et al.
Metabolic syndrome in Argentinean patients with systemic lupus erythematosus
Lupus,
October 1, 2009;
18(11):
1019 - 1025.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. Kang, T. R Mikuls, and J. R O'Dell
Hydroxychloroquine: a diabetic drug in disguise?
BMJ Case Reports,
March 2, 2009;
2009(mar01_1):
bcr0820080654 - bcr0820080654.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. K. Farmer-Boatwright and R. A.S. Roubey
Venous Thrombosis in the Antiphospholipid Syndrome
Arterioscler Thromb Vasc Biol,
March 1, 2009;
29(3):
321 - 325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R Kaiser, C M Cleveland, and L A Criswell
Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort
Ann Rheum Dis,
February 1, 2009;
68(2):
238 - 241.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Sabio, M Zamora-Pasadas, J Jimenez-Jaimez, F Albadalejo, J Vargas-Hitos, M. Rodriguez del Aguila, C Hidalgo-Tenorio, M. Gonzalez-Gay, and J. Alonso
Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain
Lupus,
September 1, 2008;
17(9):
849 - 859.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G Ruiz-Irastorza and M. Khamashta
Hydroxychloroquine: the cornerstone of lupus therapy
Lupus,
April 1, 2008;
17(4):
271 - 273.
[PDF]
|
|
|
|
|
|
|
T. Avcin and E. Silverman
Review: Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome
Lupus,
August 1, 2007;
16(8):
627 - 633.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. C. M. Wasko, H. B. Hubert, V. B. Lingala, J. R. Elliott, M. E. Luggen, J. F. Fries, and M. M. Ward
Hydroxychloroquine and Risk of Diabetes in Patients With Rheumatoid Arthritis
JAMA,
July 11, 2007;
298(2):
187 - 193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.C. Sachet, E.F. Borba, E. Bonfa, C.G.C. Vinagre, V.M. Silva, and R.C. Maranhao
Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients
Lupus,
April 1, 2007;
16(4):
273 - 278.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G Ruiz-Irastorza, M-V Egurbide, J-I Pijoan, M Garmendia, I Villar, A Martinez-Berriotxoa, J-G Erdozain, and C Aguirre
Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus
Lupus,
September 1, 2006;
15(9):
577 - 583.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M L Bertolaccini and M A Khamashta
Laboratory diagnosis and management challenges in the antiphospholipid syndrome
Lupus,
March 1, 2006;
15(3):
172 - 178.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. H. Solomon, E. W. Karlson, E. B. Rimm, C. C. Cannuscio, L. A. Mandl, J. E. Manson, M. J. Stampfer, and G. C. Curhan
Cardiovascular Morbidity and Mortality in Women Diagnosed With Rheumatoid Arthritis
Circulation,
March 11, 2003;
107(9):
1303 - 1307.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y Molad, A Gorshtein, A J Wysenbeek, D Guedj, R Majadla, A Weinberger, and M Amit-Vazina
Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort{
Lupus,
June 1, 2002;
11(6):
356 - 361.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. S. Levine, D. W. Branch, and J. Rauch
The Antiphospholipid Syndrome
N. Engl. J. Med.,
March 7, 2002;
346(10):
752 - 763.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Wozniacka, A Carter, and D P Mccauliffe
Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit
Lupus,
February 1, 2002;
11(2):
71 - 81.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D J Wallace
Antimalarials--the 'real' advance in lupus
Lupus,
June 1, 2001;
10(6):
385 - 387.
[PDF]
|
|
|
|
|
|
|
R A Levy, V S Vilela, M J Cataldo, R C Ramos, J L. Duarte, B R Tura, E M. Albuquerque, and N R Jesus
Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study
Lupus,
June 1, 2001;
10(6):
401 - 404.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D D'Cruz
Antimalarial therapy: a panacea for mild lupus?
Lupus,
March 1, 2001;
10(3):
148 - 151.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M Petri
Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort
Lupus,
March 1, 2000;
9(3):
170 - 175.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Petri
Hydroxychloroquine: past, present, future
Lupus,
February 1, 1998;
7(2):
65 - 67.
[PDF]
|
|
|
|
|
